WGS Stock Overview
Through its subsidiaries, provides genomics-related diagnostic and information services.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GeneDx Holdings Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.94 |
| 52 Week High | US$37.45 |
| 52 Week Low | US$1.16 |
| Beta | 2.36 |
| 11 Month Change | 6.22% |
| 3 Month Change | 48.90% |
| 1 Year Change | 610.57% |
| 33 Year Change | -90.32% |
| 5 Year Change | n/a |
| Change since IPO | -90.12% |
Recent News & Updates
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29
GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27Recent updates
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors
Jun 12GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Jun 06Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12Sema4 Holdings, Big Data For Precision Medicine Solutions
Jul 18Shareholder Returns
| WGS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -10.7% | 0.8% | 0.07% |
| 1Y | 610.6% | 17.5% | 22.7% |
Return vs Industry: WGS exceeded the US Healthcare industry which returned 17.5% over the past year.
Return vs Market: WGS exceeded the US Market which returned 22.6% over the past year.
Price Volatility
| WGS volatility | |
|---|---|
| WGS Average Weekly Movement | 11.3% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WGS's share price has been volatile over the past 3 months.
Volatility Over Time: WGS's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 1,000 | Katherine Stueland | www.genedx.com |
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening.
GeneDx Holdings Corp. Fundamentals Summary
| WGS fundamental statistics | |
|---|---|
| Market cap | US$860.33m |
| Earnings (TTM) | -US$117.47m |
| Revenue (TTM) | US$243.66m |
3.5x
P/S Ratio-7.3x
P/E RatioIs WGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WGS income statement (TTM) | |
|---|---|
| Revenue | US$243.66m |
| Cost of Revenue | US$107.18m |
| Gross Profit | US$136.48m |
| Other Expenses | US$253.95m |
| Earnings | -US$117.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.36 |
| Gross Margin | 56.01% |
| Net Profit Margin | -48.21% |
| Debt/Equity Ratio | 26.9% |
How did WGS perform over the long term?
See historical performance and comparison